The Effects of Recombinant Human Erythropoietin Therapy on Blood Pressure and Plasma Renin-Aldosteron Levels in Chronic Hemodialysis Patients

Year 1993, Volume: 46 Issue: 3, 429 - 434, 30.09.1993

Murat Duranay

Abstract

Hypertension is one of the most commonly seen complications in chronic hemodialysis patients treated with recombinant human
erythropoietin. The pathogenesis of hypertension is unknown. Sixteen patients are included to this study. Blood pressures, hematocrit, plasma renin activity (PRA) and aldosterone levels was monitored during a 6 months period of treatment. Hematacrit levels were significantly
increased following treatment (p<0.001), but PRA and aldosterone levels remained unchanged (p>0.05).

Keywords

Hemodialysis , r-HuEPO therapy , Hypertension , Plasma renin activity , Aldosterone.

Project Number

-

Kronik: Hemodiyaliz Hastalarnda Rekombinant insan Eritropoietin

Abstract

Rekombinant insan eritropoietin (r-HuEPO) uygulanan kronik hemodiyaliz hastalarinda sik gortilen komplikasyonlardan birisi hipertansiyondur, Gelisen hipertansiyonun patogenezi kesin olarak bilinmemektedir. Bu cahsmada, 6 ayhk r-HuEPO tedavisi stiresince 16 hastanin kan basinclarni, hematokrit, plazma renin aktivitesi (PRA) ve serum aldosteron diizeyleri izlendi. Tedaviyle hematokrit degerleri anlaml olarak yiukselirken (p<0.001), PRA ve aldosteron diizeylerinde anlaml bir degisiklik gézlenmedi (p>0.05).

Keywords

Hemodiyaliz , r-HuEPO tedavisi , Hipertansiyon , Plazma renin aktivitesi , Aldosteron.

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Abraham PA Opsahl JA Keshaviah PR et al: Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis 16 : 438-446, 1990. 2. Canadian Erythropoietin Study Group : Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300 : 573-578, 1990.
• 3. Eschbach JW : The anemia of chronic renal failure : Pathophysiology and the effects of recombinant erythropoietin, Kidney Int 35 : 134-148, 1989.
• 4. Lai KN Lui SF Leng JCK et al : Effects of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormons in patients continuous ambulatory peritoneal dialysis. Nephron 58 : 185-137, 1991.
• 5. Neff MS Kim KE Persoff M et al: Hemodynamics of uremic anemia. Circulation 43 . 876-883, 1971.
• 6. Nissenson RA Nimer SD Wolcott DL: Recombinant human erythropoietin and renal anemia : Molecular biopsy, clinical efficacy and nervous system effects. Ann Intern Med 114 : 402-416, 1991.
• 7. Onoyama K Hori K Osato S Fujishima M: Haemodynamic effect of recombinant human erythropoietin on hypotensive haemodialysis patients. Nephrol Dial Transplant 6 : 562-565, 1991.
• 8. Raine AEG Roger SD ; Effects of erythropoietin on blood pressure, Am J Kidney Dis 18 (Suppl 1) : 76-83, 1991.
• 9. Schaefer RM Hérl WH Massry SG: Treatment of renal anemia with recombinant human erythropoietin. Am J Nephrol 353-362, 1989.
• 10. Silberberg J Racine N Barre P Sniderman AD : Regression of left ventricular hypertrophy in dialysis patients following correction anemia with recombinant human erythropoietin. Can J Cardiol 6 ; 1-4, 1990.
• 11. Teruel JL Pascual J et al : Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 58 : 135-137, 1991
• 12. Winearls C : Erythropoictin. Nephrol Dial Transplant 4 : 323-326. 1989.
• 13. Yaqoob M Morris K Bell GM Ahmad R.: Supression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop. Nephrol Dial Transplant 6 : 125-128, 1991.